ASO VISUAL ABSTRACT




## ASO Visual Abstract: Management of Malignant Small Bowel Obstruction—Is Intestinal Bypass Effective Palliation?

Meagan Read, MD<sup>1,2</sup>, Benjamin D. Powers, MD<sup>1,3,4</sup>, Jose M. Pimiento, MD<sup>1,3</sup>, Danielle Laskowitz, PA-C<sup>1</sup>, Erin Mihelic, PA-C<sup>1</sup>, Iman Imanirad, MD<sup>1</sup>, Sophie Dessureault, MD<sup>1,2,3</sup>, Seth Felder, MD<sup>1,3</sup>, and Sean P. Dineen, MD<sup>1,3</sup>

<sup>1</sup>Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL; <sup>2</sup>Department of Surgery, Morsani College of Medicine, Tampa, FL; <sup>3</sup>Department of Oncologic Sciences, Morsani College of Medicine, Tampa, FL; <sup>4</sup>Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL

We investigated the outcomes of intestinal bypass for the treatment of malignant small-bowel obstruction (mSBO) (https://doi.org/10.1245/s10434-022-12204-w). We demonstrated that median OS was 6.6 months. The majority of patients were discharged to home (85.5%) and were able to tolerate diet (74.6%). Nearly half of patients



Presented as a Poster at the SSO International Conference on Surgical Cancer Care, March 2022.

© Society of Surgical Oncology 2022

Published Online: 1 August 2022

S. P. Dineen, MD e-mail: sean.dineen@moffitt.org were able to return to therapy (49.1%) and demonstrated improved survival of 11.9 months.

DISCLOSURE Authors declare no conflicts of interest.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.